Item 2.02 Results of Operations and Financial Condition.

On December 4, 2020, Foghorn Therapeutics Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit No.                                  Description

99.1                Press Release Issued by Foghorn Therapeutics Inc. on
                  December 4, 2020

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses